Pfizer boosts cancer drug roster with $14 billion Medivation deal
Pfizer Inc, beating out numerous other bidders, said it agreed to buy U.S. cancer drug company Medivation Inc for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company`s growing oncology roster.
Aug 23, 2016, 09:37 AM ISTPfizer approaches Medivation about potential takeover
Pfizer Inc has approached U.S. cancer drug maker Medivation Inc to express interest in an acquisition, raising the possibility of a bid rivaling a $9.3 billion offer by Sanofi SA, people familiar with the matter said on Tuesday.
May 04, 2016, 09:01 AM IST